A Single-Center, Open-Labeled, Phase II Trial of Modified FOLFOX6 With Bevacizumab in Patients With Advanced Biliary System Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Progression-free Survival
研究概览
简要总结
This study is for patients with biliary tract cancer that has spread and who are not candidates for surgical resection.
The purpose of this research is to determine if bevacizumab can be safely administered with Modified FOLFOX 6 and find out what effects, good and/or bad, this type of treatment has on biliary cancer.
In this study, a combination of chemotherapy, Modified FOLFOX6 and a biologic agent, bevacizumab will be tested.
Subjects on this study will receive chemotherapy and bevacizumab every 2 weeks until their disease gets worse or they are unable to tolerate treatment.
详细描述
This is a single-center, open labeled, single-arm study in patients with previously untreated unresectable biliary tract cancer. This trial will follow a Simon's two-stage optimal design. For the first stage, 9 patients will be accrued. If none of the 9 patients have controlled disease with mFOLFOX6 in combination with bevacizumab, the combination will be rejected and the trial stopped. However, if at least 1 patient of the 9 (11%) respond to treatment in the first stage, then an additional 15 patients will be entered into the second stage, for a total of 24 patients in the phase II study. If 3 (13%) or more patients respond to therapy, then the combination will be considered for further investigation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of non-resectable adenocarcinoma of the biliary tract, including carcinomas of the gallbladder, the intrahepatic or extrahepatic biliary tract, and ampullary cancer
- •Measurable or evaluable disease
- •Locally advanced disease that is inoperable ot patients who have had disease recurrence after curative surgical attempt
- •Ambulatory with an ECOG performance status of 0-1
- •Adequate organ and marrow function
- •Must agree to avoid pregnancy prior to study entry and throughout the duration of study participation
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Any prior chemotherapy
- •Patients who are receiving other investigational agents
- •Patients who have received radiotherapy to more than 25% of their bone marrow for any reason
- •Peripheral neuropathy >/= 2
- •Known brain metastases, uncontrolled seizure disorder, encephalitis
- •Prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled hypertension,unstable angina, congestive heart failure of New York Heart Association (NYHA) class 2 or greater, left ventricular ejection fraction less than 50%, clinically significant vascular disease, serious cardiac arrhythmia requiring medication, cardiomyopathy
- •History of myocardial infarction, unstable angina or stroke/transient ischemic attack (TIA) within 6 months
- •History of allergy to oxaliplatin, 5-fluoruracil (5-FU), Leucovorin, or Bevacizumab
- •History of intra-abdominal abscess within 4 weeks of study entry, abdominal fistula, gastrointestinal perforation, active peptic ulcer disease, or inflammatory bowel disease
- •Evidence of bleeding diathesis or coagulopathy
- •Serious non-healing wound, ulcer, or bone fracture
- •Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks of study entry or anticipation of need for major surgery during the course of the study
- •Minor surgical procedures such as core biopsies within 7 days before enrollment, chemotherapy port placement within 24 hours
- •Patients on full-dose anticoagulants who have out of range international normalized ratio (INR) or active bleeding
- •Concurrent malignancy unless the subject has been curatively treated and disease free for >/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
- •Known HIV or Hepatitis B or C
- •Life expectancy less than 12 weeks
- •Pregnant or nursing women
研究组 & 干预措施
"FOLFOX6" and "Bevacizumab"
Intervention = "bevacizumab" in combination with chemotherapy
Treatment of biliary system carcinoma using "Bevacizumab" in combination with "modified FOLFOX6".
干预措施: "Bevacizumab" in combination with "modified FOLFOX6". (Drug)
结局指标
主要结局
Progression-free Survival
时间窗: 2 years
Progression-free Survival is defined as the time from randomization (or study initiation) until objective tumor progression or death.
次要结局
- Safety and Toxicity(8 weeks)